Decibel Therapeutics Stock

decibeltx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $132.06MM

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine.

Register To Buy and Sell Shares

For more details on private stock price information, financing and valuation for Decibel Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Decibel Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Decibel Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Paula Cobb
Chief Operating Officer
John Keilty
Chief Data Sciences Officer
Albert Edge Ph.D
Co-Founder & Scientific Advisory Board Member
Shin-San Michael Su Ph.D
Chief Scientific Officer
Anna Trask
Chief People, Community and Culture Officer
Charles Liberman Ph.D
Co-Founder & Scientific Advisory Board Member
Ulrich Müller Ph.D
Co-Founder & Member of Scientific Advisory Board
Steven Holtzman
Chairman
Leslie Shinobu MD
Chief of Translational Research
Gabriel Corfas Ph.D
Co-Founder & Member of Scientific Advisory Board

Board Members

Craig Muir
Third Rock Ventures
Neil Exter
Third Rock Ventures
Steven Holtzman
Anthony Philippakis MD
GV
Gabriel Corfas Ph.D
Jeffrey Jonas MD
Roger Brown
Ulrich Müller Ph.D
George Scangos Ph.D
Jens Eckstein Ph.D
SR One
Troyen Brennan MD

Decibel Therapeutics’ stock FAQs

plusminus

Can you buy Decibel Therapeutics’ stock?

As Decibel Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Decibel Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge's Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.
plusminus

How to buy Decibel Therapeutics’ stock?

To invest in a private company like Decibel Therapeutics’ through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge's marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Decibel Therapeutics’ stock?

Yes, you may be able to sell your Decibel Therapeutics’ stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Decibel Therapeutics’ stock?

If you hold private company shares of Decibel Therapeutics’ - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Decibel Therapeutics’ on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.
plusminus

Is Decibel Therapeutics’ a public company?

No, Decibel Therapeutics’ is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Decibel Therapeutics’ stock price?

Decibel Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Decibel Therapeutics’ private market stock price with Forge Data.
plusminus

What is Decibel Therapeutics’ stock ticker symbol?

Decibel Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Decibel Therapeutics Appoints Healthcare Industry Veteran Christine A. Poon to its Board of Directors

Decibel Therapeutics announces appointment of biopharmaceutical leader Christine A. Poon to its board of directors.

Decibel Therapeutics Raises $55M in Series C Financing |FinSMEs

Decibel Therapeutics, which discovers and develops medicines to treat hearing loss and hearing-related disorders, raised $55M in Series C funding
Updated on: Jul 24, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.